Question 1

What is the Ipamorelin/CJC-1295 combination?

Accepted Answer

This combination pairs two distinct growth hormone secretagogue peptides. Ipamorelin (a GHS-R1a agonist) and CJC-1295 without DAC (a GHRH analog), for multi-pathway research in controlled settings.

Question 2

Why study these peptides together?

Accepted Answer

Researchers examine this combination to investigate potential synergistic signaling between GHS-R1a and GHRH receptor pathways in preclinical models of dual-pathway activation.

Question 3

How are the two peptides characterized?

Accepted Answer

Each peptide is independently verified for purity and identity before combination. Both undergo 7 rounds of analytical testing with full COA documentation.

Question 4

What research models use this combination?

Accepted Answer

This combination is examined in preclinical models studying coordinated receptor activation, signaling pathway crosstalk, and temporal dynamics of secretagogue activity.

Question 5

How is product quality verified?

Accepted Answer

Every batch undergoes 7 rounds of independent analytical testing including HPLC purity analysis, mass spectrometry identity confirmation, endotoxin screening, and sterility verification. Full Certificates of Analysis documenting all results are available for each production lot.

Question 6

Can this compound be studied alongside other research peptides?

Accepted Answer

In controlled laboratory settings, researchers may evaluate this compound in combination with other peptides to examine complementary or overlapping signaling pathways within established research protocols.

SKU	IP-CJC/IPA-10
Intended Use	For laboratory research use only. Not for human consumption.

Ipamorelin/CJC-1295 (no DAC) 5MG/5MG